$SNFCA

Profits up, sales down: inside Security National’s uneven Q1 2026

Security National Financial (SNFCA) reported a 9% increase in Q1 2026 after-tax earnings to $7.0 million, despite a 3.6% decrease in total revenues to $79.7 million. The company achieved this improved profitability through operational efficiencies, with EPS rising to $0.28 and book value per share to $17.17. While the Life Insurance segment revenue and pre-tax earnings declined, and the Funeral Homes/Cemeteries segment saw a pre-tax earnings decrease due to investment losses, the Mortgage segment significantly improved its loss by 65%.

Original reporting
Published May 11, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 11, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profits up, sales down: inside Security National’s uneven Q1 2026 — source image
Decision brief

The 30-second read

$SNFCANeutralMed
01

Why it matters

The recent earnings report indicates operational improvements offset some revenue declines, but segment weaknesses remain a concern.

02

Market read

High relevance for investors and traders focusing on regional financial stocks, especially those with exposure to insurance and mortgage segments.

03

What to watch

Potential upcoming regulatory changes or macroeconomic factors affecting the insurance and mortgage sectors that could impact SNFCA's performance.

Relevance 6/10Timing: Immediate, as the news was published on 2026-05-11

Background

Security National Financial has been navigating a challenging macroeconomic environment, impacting its revenue streams across segments.

Company-level read

Ticker impact

$SNFCANeutralMedium confidence
Context

Primary focus of the news, relevant for financial and earnings trading strategies.

Expected impact

Moderate positive impact expected in the short term due to improved profitability metrics, but mixed underlying segment performance suggests caution.

Evidence & confidence

The earnings beat and operational efficiencies are positive signals; however, segment declines and revenue decrease introduce some uncertainty.

$SNFCANeutralMedium confidence
Context

Relevance score of 0.96351 indicates high relevance for trading decisions, especially for short to medium-term traders.

Expected impact

Potential for a slight upward movement in SNFCA's stock price, contingent on investor interpretation of segment performance and earnings growth.

Evidence & confidence

Financial metrics are positive, but segment-specific declines warrant cautious optimism.

Market effects

Potential positive influence on the financial services and insurance sectors due to earnings growth

Limited regional impact, primarily affecting investors focused on North American financial stocks

Minimal, as the news pertains to a regional financial company with limited global exposure.

Counterpoint

The revenue decline and segment-specific challenges could signal underlying issues that might lead to future earnings pressure, suggesting a more cautious stance.

Key entities

  • Security National Financial

    A regional financial services company specializing in insurance, funeral services, and mortgage lending.

Related articles

$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

$AGENHighAI 8/10

After six weeks of treatment, 83% had little or no cancer remaining at surgery

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.